Latest Market Access News

Nexsen Limited (ASX:NXN) reported a 30% rise in net loss to $6.55 million for FY26, driven by ongoing investment in its Group B Streptococcus rapid diagnostic and Asia-Pacific growth initiatives following its October 2025 IPO.

OncoSil Medical lifted revenues 44% in FY26 to $1.68 million and trimmed losses by 28% to $10.86 million, buoyed by key regulatory approvals including FDA HDE and Australian TGA listings. The company is poised for commercial launches in the US and Australia, with strong clinical data underpinning its growth.

Elixir Energy has marked FY26 with major progress in Queensland’s Taroom Trough, expanding contingent gas resources by 32% and securing a strategic $16.6 million capital raise led by Omega Oil and Gas. The company’s operational advances and government backing position it as a key player in Australia’s energy security landscape.

Almonty Industries will voluntarily delist from the ASX by September 1, 2026, consolidating its trading on Nasdaq and Frankfurt amid strategic shifts in its market presence.

Memphasys has secured early Thai FDA approval for its Felix™ System, triggering a three-year exclusive distribution deal with IVF Envimed and prompting additional orders amid strong clinic interest.

Rhythm Biosciences marked its transition to commercialisation with first sales of ColoSTAT® and geneType™ tests, despite a 55% increase in loss to $5.93 million. The company expanded market access and secured manufacturing agreements, while NHS England began evaluating ColoSTAT® for bowel cancer screening.

Genetic Signatures (ASX: GSS) and Microba Life Sciences (ASX: MAP) are in early talks about merging to form a larger infectious disease diagnostics entity, combining rapid pathogen detection with microbiome profiling. The proposed group would have FY2026 pro forma revenue of around A$29 million and a stronger financial footing.

PolyNovo reported a 16.1% rise in FY26 revenue to AUD 150 million, driven by strong global sales and manufacturing expansion, yet net profit fell 44% due to a significant asset write-off from an R&D centre fire and lower tax benefits.

Scales Corporation delivered a record first half in 2026 with revenues soaring 105% to NZ$762.1 million and underlying EBITDA up 18% to NZ$102.2 million. The diversified agribusiness raised its full year profit guidance despite challenges in Europe and the Middle East.

Terragen Holdings posted a slight increase in net loss to AUD 3.75 million for FY2026, while advancing key commercial trials and securing a $7 million equity raise to fuel growth.

Control Bionics has secured MHRA registration for its NeuroStrip device, unlocking commercial supply in Great Britain and launching early trials with leading UK institutions.

International Graphite is advancing Australia’s first commercial graphite micronising plant at Collie, targeting commissioning by mid-2027. The facility promises a diverse range of superfine graphite products and potential annual EBITDA up to AUD 14.2 million based on current market conditions.